Twelve partner institutions from the United States and Canada are collaborating to develop novel treatments to improve quality of life and long-term survival for patients fighting malignant brain tumors.
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
